Who
Eric D. Shaff
Director
Company insider
Files Form 4 as: CEO and President, Seres Therapeutics; Director, Sigilon Therapeutics.
In numbers
- Trades disclosed
- 113
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $920K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 25 Jun 2015
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,197263 at $4.55 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,197263 at $4.55 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —722 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —390 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —390 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —332 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —332 at $0.00 | filing |
| 15 Aug 2026filed 18 Aug 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —722 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,950259 at $7.53 | filing |
| 18 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,950259 at $7.53 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —722 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —391 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —391 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —331 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —331 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —722 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —723 | filing |
| 15 Feb 2026filed 18 Feb 2026 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,194259 at $8.47 | filing |
News
Critical Contrast: Seres Therapeutics (NASDAQ:MCRB) & BioLineRx (NASDAQ:BLRX)MCRB · tickerreport.com · 21 Oct 2026MDxHealth (NASDAQ:MDXH) versus Seres Therapeutics (NASDAQ:MCRB) Financial ComparisonMCRB · tickerreport.com · 21 Oct 2026
0 headlines in the last 90 days name Eric D. Shaff; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.